Towards Precision Radiation Oncology: Endocrine Therapy Resistance as a Biomarker for Radiation Resistance in ER-Positive Breast Cancer

被引：0
|
作者：
Udden, S. M. Nashir
Rahimi, Asal
Kim, Dong W. Nathan
Alluri, Prasanna
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P4-02-08
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-02-08
引用
下载
收藏
页数：2
相关论文
共 50 条
  • [11] Correlation between serum lipid levels and endocrine resistance in patients with ER-positive breast cancer
    Sun, Hong
    Hu, Congting
    Zheng, Xiaohan
    Zhuang, Jie
    Wei, Xiaoxia
    Cai, Jiaqin
    MEDICINE, 2023, 102 (41) : E35048
  • [12] Neoadjuvant endocrine therapy: A potential strategy for ER-positive breast cancer
    Li-Tong Yao
    Mo-Zhi Wang
    Meng-Shen Wang
    Xue-Ting Yu
    Jing-Yi Guo
    Tie Sun
    Xin-Yan Li
    Ying-Ying Xu
    World Journal of Clinical Cases, 2019, (15) : 1937 - 1953
  • [13] Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in ER-positive breast cancer
    Arnedos, M.
    Drury, S.
    Afentakis, M.
    Hills, M.
    Salter, J.
    Smith, I. E.
    Dowsett, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [14] Neoadjuvant endocrine therapy: A potential strategy for ER-positive breast cancer
    Yao, Li-Tong
    Wang, Mo-Zhi
    Wang, Meng-Shen
    Yu, Xue-Ting
    Guo, Jing-Yi
    Sun, Tie
    Li, Xin-Yan
    Xu, Ying-Ying
    WORLD JOURNAL OF CLINICAL CASES, 2019, 7 (15) : 1937 - 1953
  • [15] Therapeutic strategy for ERα mutation driven-endocrine resistance in ER-positive breast cancers
    Kim, Jin-Ah
    Fuqua, Suzanne A. W.
    CANCER RESEARCH, 2018, 78 (04)
  • [16] Heregulin Drives Endocrine Resistance by Altering IL-8 Expression in ER-Positive Breast Cancer
    Papadimitropoulou, Adriana
    Vellon, Luciano
    Atlas, Ella
    Vander Steen, Travis
    Cuyas, Elisabet
    Verdura, Sara
    Espinoza, Ingrid
    Menendez, Javier A.
    Lupu, Ruth
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (20) : 1 - 15
  • [17] Understanding response and resistance to oestrogen deprivation in ER-positive breast cancer
    Patani, N.
    Martin, L-A
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2014, 382 (01) : 683 - 694
  • [18] ESR1 mutations are not a mechanism of primary resistance to aromatase inhibitors in ER-positive breast cancer treated with neoadjuvant endocrine therapy
    Reinert, Tomas
    Ramalho, Susana
    Vasconcelos, Vivian C. A.
    Silva, Leonardo R.
    Silva, Ana Elisa R.
    Andrade, Camila A.
    Kraft, Maria Beatriz P. L.
    Coelho, Guilherme P.
    Mandelli, Jovana
    Binotto, Monique
    Cabello, Cesar
    Silva, Geisilene R. P.
    Bines, Jose
    Barrios, Carlos H.
    Ellis, Matthew J.
    Graudenz, Marcia S.
    CANCER RESEARCH, 2020, 80 (04)
  • [19] Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease
    Jansen, Maurice P. H. M.
    Sas, Leen
    Sieuwerts, Anieta M.
    Van Cauwenberghe, Caroline
    Ramirez-Ardila, Diana
    Look, Maxime
    Ruigrok-Ritstier, Kirsten
    Finetti, Pascal
    Bertucci, Francois
    Timmermans, Mieke M.
    van Deurzen, Carolien H. M.
    Martens, John W. M.
    Simon, Iris
    Roepman, Paul
    Linn, Sabine C.
    van Dam, Peter
    Kok, Marleen
    Lardon, Filip
    Vermeulen, Peter B.
    Foekens, John A.
    Dirix, Luc
    Berns, Els M. J. J.
    Van Laere, Steven
    MOLECULAR ONCOLOGY, 2015, 9 (06) : 1218 - 1233
  • [20] Comprehensive analysis of a cuproptosis-related ceRNA network implicates a potential endocrine therapy resistance mechanism in ER-positive breast cancer
    Zhang, Dongni
    Lu, Wenping
    Zhuo, Zhili
    Wang, Yanan
    Zhang, Weixuan
    Zhang, Mengfan
    BMC MEDICAL GENOMICS, 2023, 16 (01)
12345